Pharmacological Properties of Salmeterol

Pharmacological Properties of Inhaled Salmeterol in Healthy Trained Males

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02558088

Enrollment

Registered

2015-09-23

Start date

2014-09-30

Completion date

2016-07-31

Last updated

2017-01-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pharmacokinetics in Healthy Young Men

Keywords

salmeterol, pharmacokinetics, doping, beta2-agonists, long-acting beta2-agonists

Brief summary

The objective of the study is to help establish a urinary threshold for salmeterol on the World Anti-doping Agency prohibited list, to avoid supratherapeutic of this substance in competitive sports. Hence, there is no hypothesis as such.

Interventions

DRUGSalmeterol

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

MALE

Age

18 Years to 45 Years

Healthy volunteers

Yes

Inclusion criteria

* Male * 18-45 years * Healthy

Exclusion criteria

* Chronic disease * Smoking * Habitual use of medicine * Allergy towards salmeterol * Unable to exercise on a bike ergometer

Design outcomes

Primary

Measure	Time frame
Urine concentration of salmeterol	0-24 hours after administration of the study drug

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026